Lantheus Holdings(US:LNTH)2025-05-07 11:16Financial Performance - Lantheus reported first quarter 2025 revenues of $3728 million, a 08% increase compared to $369975 million in the first quarter of 2024[62, 78] - Adjusted EPS for the first quarter of 2025 was $153, a 95% decrease compared to $169 in the first quarter of 2024[17, 79] - The company's net income for 1Q 2025 was $72945 million, a 443% decrease compared to $131066 million for 1Q 2024[78] Strategic Initiatives - Lantheus is integrating Evergreen Theragnostics Inc and planning to acquire Life Molecular Imaging Ltd to strengthen radiodiagnostic and therapeutic capabilities[17, 24] - The company is divesting its SPECT business to SHINE Technologies, LLC, with the transaction expected to close by the end of 2025[17, 24] - Lantheus has a strong cash position with $9385 million in cash on hand and $750 million available in revolving credit[17, 66] Product Performance and Market Outlook - PYLARIFY net sales were $2577 million in 1Q 2025, representing a 05% decrease compared to 1Q 2024[37, 62] - DEFINITY net sales were $792 million in 1Q 2025, a 35% increase year-over-year[47, 62] - The PSMA PET market may exceed $35 billion by the end of the decade, with an annual scan potential of approximately 750,000[40, 41]